PROCEPT BioRobotics Corporation (PRCT) Reports Q4 Loss, Tops Revenue Estimates

Group 1: Financial Performance - PROCEPT BioRobotics reported a quarterly loss of $0.35 per share, which aligns with the Zacks Consensus Estimate, an improvement from a loss of$0.54 per share a year ago [1] - The company posted revenues of $68.24 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 2.40$43.58 million in the same quarter last year [2] - Over the last four quarters, PROCEPT BioRobotics has surpassed consensus EPS estimates three times and topped consensus revenue estimates four times [2][3] Group 2: Stock Performance and Outlook - PROCEPT BioRobotics shares have declined approximately 19.1% since the beginning of the year, contrasting with the S&P 500's gain of 1.7% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.32 on revenues of$66.34 million, and for the current fiscal year, it is -$1.27 on revenues of$315.64 million [7] - The estimate revisions trend for PROCEPT BioRobotics is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Instruments industry, to which PROCEPT BioRobotics belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]